Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 201,581 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 30,421 · Balance 201,581 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2036-06-16 | Direct | 49,579 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 49,579 · Balance 49,579 F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:29 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 49,579 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0000905148-26-003056 · form4.xml · derivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,579 Underlying: Common Stock · 49,579 shares Expires 2036-06-16 F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:29 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 30,421 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003056 · form4.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,581 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 22:48 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 50,790 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000905148-25-002235 · form4.xml · derivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,790 Underlying: Common Stock · 50,790 shares Expires 2035-06-17 F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 22:48 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 29,210 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002235 · form4.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,160 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:13 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001415889-25-002263 · form4-01292025_090107.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,417 Underlying: Common Stock · 3,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:13 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 3,000 | $4.65 | $13,935.00 |
DisclosureSEC source: 0001415889-25-002263 · form4-01292025_090107.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,950 F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.52 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:13 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 3,000 | $2.93 | $8,796.00 |
DisclosureSEC source: 0001415889-25-002263 · form4-01292025_090107.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| December 26, 2024 Filed Dec 30, 2024 21:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001415889-24-030230 · form4-12302024_041201.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,417 Underlying: Common Stock · 3,000 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 26, 2024 Filed Dec 30, 2024 21:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 3,000 | $4.01 | $12,021.00 |
DisclosureSEC source: 0001415889-24-030230 · form4-12302024_041201.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,950 F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.995 to $4.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 26, 2024 Filed Dec 30, 2024 21:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 3,000 | $2.93 | $8,796.00 |
DisclosureSEC source: 0001415889-24-030230 · form4-12302024_041201.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 483 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001415889-24-028839 · form4-12102024_041201.xml · derivative · entry 10 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,417 Underlying: Common Stock · 483 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 1,121 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-24-028839 · form4-12102024_041201.xml · derivative · entry 9 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,121 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 891 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001415889-24-028839 · form4-12102024_041201.xml · derivative · entry 8 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 891 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 2,495 | $3.79 | $9,458.55 |
DisclosureSEC source: 0001415889-24-028839 · form4-12102024_041201.xml · nonDerivative · entry 6 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,950 F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.705 to $3.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 483 | $2.93 | $1,416.16 |
DisclosureSEC source: 0001415889-24-028839 · form4-12102024_041201.xml · nonDerivative · entry 5 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 1,121 | $1.64 | $1,839.56 |
DisclosureSEC source: 0001415889-24-028839 · form4-12102024_041201.xml · nonDerivative · entry 4 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 891 | $2.93 | $2,607.07 |
DisclosureSEC source: 0001415889-24-028839 · form4-12102024_041201.xml · nonDerivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 505 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001415889-24-028839 · form4-12102024_041201.xml · derivative · entry 7 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 891 Underlying: Common Stock · 505 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 505 | $3.70 | $1,869.01 |
DisclosureSEC source: 0001415889-24-028839 · form4-12102024_041201.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,950 F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.70 to $3.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 505 | $2.93 | $1,477.63 |
DisclosureSEC source: 0001415889-24-028839 · form4-12102024_041201.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 20:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001415889-24-025749 · form4-10302024_041006.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,396 Underlying: Common Stock · 3,000 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 20:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 3,000 | $3.72 | $11,166.00 |
DisclosureSEC source: 0001415889-24-025749 · form4-10302024_041006.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,950 F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.70 to $3.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 20:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 3,000 | $2.93 | $8,778.00 |
DisclosureSEC source: 0001415889-24-025749 · form4-10302024_041006.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 20:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001415889-24-024090 · form4-09302024_040901.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,396 Underlying: Common Stock · 3,000 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 20:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 3,000 | $3.82 | $11,460.00 |
DisclosureSEC source: 0001415889-24-024090 · form4-09302024_040901.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,950 F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.80 to $3.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 20:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 3,000 | $2.93 | $8,778.00 |
DisclosureSEC source: 0001415889-24-024090 · form4-09302024_040901.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001415889-24-022448 · form4-08282024_040806.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,396 Underlying: Common Stock · 3,000 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 3,000 | $4.28 | $12,840.00 |
DisclosureSEC source: 0001415889-24-022448 · form4-08282024_040806.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,950 F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.23 to $4.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 3,000 | $2.93 | $8,778.00 |
DisclosureSEC source: 0001415889-24-022448 · form4-08282024_040806.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001415889-24-020343 · form4-07302024_080732.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,396 Underlying: Common Stock · 3,000 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 3,000 | $4.75 | $14,238.00 |
DisclosureSEC source: 0001415889-24-020343 · form4-07302024_080732.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,950 F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.63 to $4.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:39 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 3,000 | $2.93 | $8,778.00 |
DisclosureSEC source: 0001415889-24-020343 · form4-07302024_080732.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:18 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 4,956 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001415889-24-018635 · form4-07012024_090717.xml · derivative · entry 5 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,396 Underlying: Common Stock · 4,956 shares Expires 2027-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:18 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 5,044 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-24-018635 · form4-07012024_090717.xml · derivative · entry 4 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,121 Underlying: Common Stock · 5,044 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:18 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 10,000 | $3.99 | $39,900.00 |
DisclosureSEC source: 0001415889-24-018635 · form4-07012024_090717.xml · nonDerivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,950 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.93 to $4.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:18 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 4,956 | $2.93 | $14,501.26 |
DisclosureSEC source: 0001415889-24-018635 · form4-07012024_090717.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:18 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 5,044 | $1.64 | $8,277.20 |
DisclosureSEC source: 0001415889-24-018635 · form4-07012024_090717.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 40,701 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001415889-24-016709 · form4-06132024_090639.xml · derivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,701 Underlying: Common Stock · 40,701 shares Expires 2034-06-10 F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 11, 2025, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 21,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016709 · form4-06132024_090639.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,950 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 11, 2025, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 20:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-009334 · form4-03282024_040349.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 617 Underlying: Common Stock · 5,000 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 20:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 5,000 | $4.41 | $22,025.00 |
DisclosureSEC source: 0001415889-24-009334 · form4-03282024_040349.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.37 to $4.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 20:31 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 5,000 | $2.14 | $10,710.00 |
DisclosureSEC source: 0001415889-24-009334 · form4-03282024_040349.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-005727 · form4-02282024_040201.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,617 Underlying: Common Stock · 5,000 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option vested monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 5,000 | $4.60 | $23,005.00 |
DisclosureSEC source: 0001415889-24-005727 · form4-02282024_040201.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.51 to $4.625, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 5,000 | $2.14 | $10,710.00 |
DisclosureSEC source: 0001415889-24-005727 · form4-02282024_040201.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-001975 · form4-01302024_040101.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,617 Underlying: Common Stock · 5,000 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F3 · derivative.exercise_date: The shares underlying this option vested monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 5,000 | $5.12 | $25,585.00 |
DisclosureSEC source: 0001415889-24-001975 · form4-01302024_040101.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.04 to $5.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 5,000 | $2.14 | $10,710.00 |
DisclosureSEC source: 0001415889-24-001975 · form4-01302024_040101.xml · nonDerivative · entry 1 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-059910 · doc4.xml · derivative · entry 3 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,617 Underlying: Common Stock · 5,000 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F3 · derivative.exercise_date: The shares underlying this option vested monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 21:30 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 5,000 | $4.53 | $22,650.00 |
DisclosureSEC source: 0001209191-23-059910 · doc4.xml · nonDerivative · entry 2 Johnston John Joseph · CIK 0001874850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,583 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.455 to $4.585, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.